MDM2基因SNP309多态性与白血病易感性关系的Meta分析_《中国循证医学杂志》

作者：

郑沁 , 刘华 , 曾婷婷 , 叶远馨 , 蒋能刚 ,  粟军

四川大学华西医院实验医学科（成都 610041）;

关键词：

MDM2 白血病单核苷酸多态性系统评价 Meta分析病例-对照研究

DOI：

10.7507/1672-2531.20130030

视频：

导出 下载 收藏 扫码 引用

摘要 全文 图表 视频 参考文献 施引文献 补充材料

目的　系统评价小鼠双微体基因2（murine double minute 2，MDM2）启动子309位点单核苷酸多态性（single nucleotide polymorphism，SNP309）与白血病易感性的关系。
方法　计算机检索Ovid、EBSCO、PubMed、CNKI、CBM、VIP及WanFang Data，搜集相关病例-对照研究，检索时限为1990年1月～2012年6月。按纳入与排除标准筛选文献、提取资料并评价纳入研究的方法学质量后，采用RevMan 5.0、Stata 10.0软件进行Meta分析，计算合并OR值及其95%CI，并进行敏感性分析及发表偏倚评估。
结果　共纳入8篇文献9个研究，累计病例1 821例，对照5 642例。Meta分析结果显示：携带G等位基因者对于T等位基因者，白血病易感性增加［OR=1.26，95%CI（1.08，1.46），P=0.003］；基因型为GG的人群白血病发病风险高于基因型为TT的人群［OR=1.46，95%CI（1.02，2.10），P=0.04］；隐性模型中亚洲人GG纯合子基因型人群白血病发病风险高于GT+TT基因型人群［OR=2.00，95%CI（1.37，2.92），P=0.000 3］。未见明显发表偏倚。
结论　MDM2基因SNP309多态性与白血病易感性相关，等位基因G可能是白血病易感的危险因素。

引用本文： 郑沁,刘华,曾婷婷,叶远馨,蒋能刚,粟军. MDM2基因SNP309多态性与白血病易感性关系的Meta分析. 中国循证医学杂志, 2013, 13(2): 170-175. doi: 10.7507/1672-2531.20130030 复制

1.	Satoh Y, Matsumura I, Tanaka H, et al. C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells. Leukemia, 2012, 26(2): 303-311.
2.	Vogelstein B, Lane D, Levine AJ. Surfing the P53 network. Nature, 2000, 408(6810): 307-310.
3.	Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol, 2003, 13(1): 49-58.
4.	Bond GL, Hu W, Bond EE, et al. A single nueleotide polymorphism in the MDM2 promoter attenuates the P53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 2004, 119(5): 591-602.
5.	吴晓梅, 时玥, 时景璞, 等. 中国汉族人群脑出血患者血管紧张素转换酶基因插入/缺失多态性的Meta分析. 中国循证医学杂志, 2009, 9(12): 1323-1327.
6.	Ellis NA, Huo D, Yildiz O, et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood, 2008, 112(3): 741-749.
7.	Zenz T, Habe S, Benner A, et al. The MDM2-309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia. Haematologica, 2008, 93(7): 1111-1113.
8.	Phang BH, Linn YC, Li H, et al. MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. Eur J Cancer, 2008, 44(5): 760-766.
9.	Chen YL, Chang YS, Chang JG, et al. Genotyping of single nucleotide polymorphism in MDM2 genes by universal fluorescence primer PCR and capillary electrophoresis. Anal Bioanal Chem, 2009, 394(5): 1291-1297.
10.	Xiong X, Wang M, Wang L, et al. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk Res, 2009, 33(11):1454- 1458.
11.	Do TN, Ucisik-Akkaya E, Davis CF, et al. TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility. Cancer Genet Cytogenet, 2009, 195(1): 31-36.
12.	Phillips CL, Gerbing R, Alonzo T, et al. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer, 2010, 55(2): 248- 253.
13.	Dong HJ, Fang C, Fan L, et al. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL. Int J Cancer, 2012, 130(9): 2054-2061.
14.	Yi ZH. A meta analysis on expression of cyclooxygenase-2 in gastric carcinoma. Bulletin of Chinese Cancer, 2007, 16(5): 365-367.
15.	Dharel N, Kato N, Muroyama R, et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res, 2006,12(16): 4867-4871.
16.	Onat OE, Tez M, Ozcelik T, et al. MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res, 2008, 26(5A): 3473-3475.
17.	Hong Y, Miao X, Zhang X, et al. The role of p53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res, 2005, 65(20): 9582-9587.

1. Satoh Y, Matsumura I, Tanaka H, et al. C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells. Leukemia, 2012, 26(2): 303-311.
2. Vogelstein B, Lane D, Levine AJ. Surfing the P53 network. Nature, 2000, 408(6810): 307-310.
3. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol, 2003, 13(1): 49-58.
4. Bond GL, Hu W, Bond EE, et al. A single nueleotide polymorphism in the MDM2 promoter attenuates the P53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 2004, 119(5): 591-602.
5. 吴晓梅, 时玥, 时景璞, 等. 中国汉族人群脑出血患者血管紧张素转换酶基因插入/缺失多态性的Meta分析. 中国循证医学杂志, 2009, 9(12): 1323-1327.
6. Ellis NA, Huo D, Yildiz O, et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood, 2008, 112(3): 741-749.
7. Zenz T, Habe S, Benner A, et al. The MDM2-309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia. Haematologica, 2008, 93(7): 1111-1113.
8. Phang BH, Linn YC, Li H, et al. MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. Eur J Cancer, 2008, 44(5): 760-766.
9. Chen YL, Chang YS, Chang JG, et al. Genotyping of single nucleotide polymorphism in MDM2 genes by universal fluorescence primer PCR and capillary electrophoresis. Anal Bioanal Chem, 2009, 394(5): 1291-1297.
10. Xiong X, Wang M, Wang L, et al. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk Res, 2009, 33(11):1454- 1458.
11. Do TN, Ucisik-Akkaya E, Davis CF, et al. TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility. Cancer Genet Cytogenet, 2009, 195(1): 31-36.
12. Phillips CL, Gerbing R, Alonzo T, et al. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer, 2010, 55(2): 248- 253.
13. Dong HJ, Fang C, Fan L, et al. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL. Int J Cancer, 2012, 130(9): 2054-2061.
14. Yi ZH. A meta analysis on expression of cyclooxygenase-2 in gastric carcinoma. Bulletin of Chinese Cancer, 2007, 16(5): 365-367.
15. Dharel N, Kato N, Muroyama R, et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res, 2006,12(16): 4867-4871.
16. Onat OE, Tez M, Ozcelik T, et al. MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res, 2008, 26(5A): 3473-3475.
17. Hong Y, Miao X, Zhang X, et al. The role of p53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res, 2005, 65(20): 9582-9587.

《中国循证医学杂志》

MDM2基因SNP309多态性与白血病易感性关系的Meta分析

摘要 全文 图表 视频 参考文献 施引文献 补充材料

上一篇

下一篇

Format

Content

《中国循证医学杂志》

MDM2基因SNP309多态性与白血病易感性关系的Meta分析

摘要 全文 图表 视频 参考文献 施引文献 补充材料

上一篇

下一篇

Format

Content

摘要全文图表视频参考文献施引文献补充材料